Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: The GAUSS-3 randomized clinical trial

JAMA - Journal of the American Medical Association

Volumn 315, Issue 15, 2016, Pages 1580-1590

  Nissen, Steven E ^a   Stroes, Erik ^b,am   Dent Acosta, Ricardo E ^c   Rosenson, Robert S ^d,az   Lehman, Sam J ^e,p   Sattar, Naveed ^f   Preiss, David ^g,av   Bruckert, Eric ^h,aa   Češka, Richard ^i,j   Lepor, Norman ^k   Ballantyne, Christie M ^l   Gouni Berthold, Ioanna ^m,ae   Elliott, Mary ^c   Brennan, Danielle M ^a   Wasserman, Scott M ^c   Somaratne, Ransi ^c   Scott, Rob ^c   Stein, Evan A ⁿ   Sullivan, David ^o   Kostner, Karam ^q   Don Wauchope, Andrew ^r   Hartleib, Michael ^s   Baass, Alexis ^t   Bergeron, Jean ^u   Joy, Tisha ^v   Adamkova, Vera ^w   Blaha, Vladimir ^x   Jeppesen, Jorgen ^y   Jensen, Henrik Kjaerulf ^z   Krempf, Michel ^ab   Bully, Chantal ^ac   Bosiljanoff, Peter ^ad   Steinhagen Thiessen, Elisabeth ^af   Pintus, Paolo ^ag   Borghi, Claudio ^ah   Sampietro, Tiziana ^ai   Vigna, Giovanni Battista ^aj   Mannarino, Elmo ^ak   Pozzi, Claudio ^al   Liem, Anho ^an   Van Leendert, Rudolf ^ao   Scott, Russell ^ap   Kjaernli, Thorbjorn ^aq   Langslet, Gisle ^ar   Jacovides, Andrew ^as   Klug, Eric ^at   Blom, Dirk ^au   Neely, Dermot ^aw   Dawson, Charlotte ^ax   Miller, Michael ^ay   McCullum, Kevin ^ba   Rocco, Michael ^a   Shah, Prediman ^bb   Rosenblit, Paul ^bc   Pokrywka, Gregory ^bd   Blazing, Michael ^be   Toth, Peter ^bf   Moriarty, Patrick ^bg   Rubenfire, Melvyn ^bh   Morris, Pamela ^bi   Quyyumi, Arshed ^bj   Kopecky, Stephen ^bk   more..

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c AMGEN INC   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^e FLINDERS UNIVERSITY   (Australia)

^f UNIVERSITY OF GLASGOW   (United Kingdom)

^g UNIVERSITY OF OXFORD   (United Kingdom)

^h University of Paris   (France)

ⁱ CHARLES UNIVERSITY   (Czech Republic)

^j CHARLES UNIVERSITY   (Czech Republic)

^k UNIVERSITY OF CALIFORNIA   (United States)

^l BAYLOR COLLEGE OF MEDICINE   (United States)

^m UNIVERSITY OF COLOGNE   (Germany)

ⁿ Metab and Atherosclerosis Res Ctr   (United States)

^o ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^p UNIVERSITY OF ADELAIDE   (Australia)

^q Dr Heart Pty Ltd ^*  (Australia)

^r HAMILTON GENERAL HOSPITAL   (Canada)

^s Kawartha Cardiology Clinical Trials   (Canada)

^t CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^u Clinique des Maladies Lipidiques de Quebec Incorporated   (Canada)

^v LONDON HEALTH SCIENCES CENTRE   (Canada)

^w INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

^x UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^y GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^z AARHUS UNIVERSITY HOSPITAL   (Denmark)

^aa PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^ab CHU de Nantes   (France)

^ac Groupe Hospitalier Mutualiste de Grenoble   (France)

^ad Klinikum Dritter Orden   (Germany)

^ae UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^af CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^ag BROTZU HOSPITAL   (Italy)

^ah UNIVERSITY OF BOLOGNA   (Italy)

^ai Fondazione Toscana Gabriele Monasterio   (Italy)

^aj UNIVERSITY HOSPITAL OF FERRARA   (Italy)

^ak UNIVERSITY OF PERUGIA   (Italy)

^al PARKINSON INSTITUTE   (Italy)

^am ACADEMIC MEDICAL CENTER   (Netherlands)

^an SINT FRANCISCUS GASTHUIS   (Netherlands)

^ao Albert Schweitzer Ziekenhuis Locatie Zwijndrecht   (Netherlands)

^ap Lipids and Diabetes Research Group   (New Zealand)

^aq Medi 3 Klinikk   (Norway)

^ar OSLO UNIVERSITY HOSPITAL   (Norway)

^as Midrand Medical Centre   (South Africa)

^at Sunninghill Hospital   (South Africa)

^au Lipid Laboratory   (South Africa)

^av GLASGOW ROYAL INFIRMARY   (United Kingdom)

^aw ROYAL VICTORIA INFIRMARY   (United Kingdom)

^ax Queen Elizabeth Hospital   (United Kingdom)

^ay UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

^az MOUNT SINAI MEDICAL CENTER   (United States)

^ba Department of Medicine   (United States)

^bb CEDARS SINAI MEDICAL CENTER   (United States)

^bc Diabetes/Lipid Management and Research Center   (United States)

^bd IRC Clinics Inc   (United States)

^be DUKE UNIVERSITY   (United States)

^bf IRC Clinics Inc ^*  (United States)

^bg UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^bh UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^bi MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^bj EMORY UNIVERSITY HOSPITAL   (United States)

^bk MAYO CLINIC ROCHESTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CREATINE KINASE; EVOLOCUMAB; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; BIOLOGICAL MARKER; HYPOCHOLESTEROLEMIC AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTHRALGIA; ARTICLE; BACKACHE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; CROSSOVER PROCEDURE; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG RECHALLENGE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GASTROESOPHAGEAL REFLUX; HEADACHE; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; INFLUENZA; INJECTION SITE REACTION; INSOMNIA; ISCHEMIC HEART DISEASE; LIMB PAIN; MAJOR CLINICAL STUDY; MALE; MUSCLE DISEASE; MUSCLE SPASM; MUSCLE WEAKNESS; MUSCULOSKELETAL PAIN; MYALGIA; NAUSEA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RHINOPHARYNGITIS; TREATMENT DURATION; URINARY TRACT INFECTION; BLOOD; CHEMICALLY INDUCED; MIDDLE AGED; MUSCULAR DISEASES; MYOSITIS; RHABDOMYOLYSIS; TIME FACTOR;

ADULT; ANTIBODIES, MONOCLONAL; ANTICHOLESTEREMIC AGENTS; ATORVASTATIN CALCIUM; BIOMARKERS; CHOLESTEROL, LDL; CREATINE KINASE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; EZETIMIBE; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; MUSCULAR DISEASES; MYALGIA; MYOSITIS; RHABDOMYOLYSIS; TIME FACTORS;

EID: 84964330289     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2016.3608     Document Type: Article

References (19)

1. Stone NJ, Robinson JG, Lichtenstein AH, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63(25, pt B):2889-2934.
2. Stroes ES, Thompson PD, Corsini A, et al; European Atherosclerosis Society Consensus Panel. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J. 2015;36 (17):1012-1022.
3. Zhang H, Plutzky J, Skentzos S, et al. Discontinuation of statins in routine care settings: a cohort study. Ann Intern Med. 2013;158(7):526-534.
4. Athyros VG, Tziomalos K, Kakafika AI, Koumaras H, Karagiannis A, Mikhailidis DP. Effectiveness of ezetimibe alone or in combination with twice a week atorvastatin (10mg) for statin intolerant high-risk patients. Am J Cardiol. 2008;101(4):483-485.
5. Mampuya WM, Frid D, Rocco M, et al. Treatment strategies in patients with statin intolerance: the Cleveland Clinic experience. Am Heart J. 2013;166 (3):597-603.
6. Moriarty PM, Thompson PD, Cannon CP, et al; ODYSSEY ALTERNATIVE Investigators. Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: the ODYSSEY ALTERNATIVE randomized trial. J Clin Lipidol. 2015;9(6):758-769.
7. Sullivan D, Olsson AG, Scott R, et al. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. JAMA. 2012; 308(23):2497-2506.
8. Stroes E, Colquhoun D, Sullivan D, et al; GAUSS-2 Investigators. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab. J Am Coll Cardiol. 2014;63(23):2541-2548.
9. Nissen SE, Dent R, Rosenson RS, et al. Comparison of PCSK9 inhibitor evolocumab versus ezetimibe in statin-intolerant patients: design of the Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects 3 (GAUSS 3) trial [published online March 4, 2016]. Clin Cardiol. doi:10.1002/clc.22518.
10. Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika. 1988; 75:800-802.
11. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143-3421.
12. Stein EA, Ballantyne CM, Windler E, et al. Efficacy and tolerability of fluvastatin XL 80mg alone, ezetimibe alone, and the combination of fluvastatin XL 80mg with ezetimibe in patients with a history of muscle-related side effects with other statins. Am J Cardiol. 2008;101(4):490-496.
13. Taylor BA, Lorson L, White CM, Thompson PD. A randomized trial of coenzyme Q10 in patients with confirmed statinmyopathy. Atherosclerosis. 2015;238(2):329-335.
14. Stiles S. FDA Says No to Ezetimibe Secondary-Prevention Indication. Medscape website. http://www.medscape.com/viewarticle/858944. February 15, 2016. Accessed February 17, 2016.
15. Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER). ClinicalTrials.gov website. http://clinicaltrials.gov/show/NCT01764633. Accessed February 18, 2016.
16. Schwartz GG, Bessac L, Berdan LG, et al. Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY Outcomes trial. Am Heart J. 2014;168(5):682-689.
17. The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects (SPIRE-1). ClinicalTrials.gov website. http://clinicaltrials.gov/show/NCT01975376. Accessed February 18, 2016.
18. Tobert JA, Newman CB. Statin tolerability: in defence of placebo-controlled trials [published online August 28, 2015]. Eur J Prev Cardiol. doi:10.1177/2047487315602861.
19. Sabatine MS, Giugliano RP, Wiviott SD, et al; Open-Label Study of Long-Term Evaluation against LDL Cholesterol (OSLER) Investigators. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372(16): 1500-1509.